- Stocks
- Healthcare
- NASDAQ: ALKS

Price (delayed)

$19.45

Market cap

$3.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$3.23B

Sector: Healthcare

Industry: Biotechnology

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by

The EPS has dropped by 52% since the previous quarter but it is up by 44% year-on-year

Alkermes's net income has plunged by 51% from the previous quarter but it has increased by 44% YoY

The debt has grown by 41% YoY and by 6% from the previous quarter

Alkermes's gross profit has decreased by 13% YoY and by 13% from the previous quarter

What are the main financial stats of ALKS

Market
Valuations
Earnings

Shares outstanding

159.24M

Market cap

$3.1B

Enterprise value

$3.23B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.9

Price to sales (P/S)

2.97

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.11

Revenue

$1.04B

EBIT

-$87.88M

EBITDA

-$6.02M

Free cash flow

$41.27M

Per share
Balance sheet
Liquidity

EPS

-$0.7

Free cash flow per share

$0.26

Book value per share

$6.7

Revenue per share

$6.54

TBVPS

$10.99

Total assets

$1.95B

Total liabilities

$882.75M

Debt

$410.16M

Equity

$1.07B

Working capital

$672.71M

Debt to equity

0.38

Current ratio

2.53

Quick ratio

2.08

Net debt/EBITDA

-22.77

Margins
Efficiency
Dividend

EBITDA margin

-0.6%

Gross margin

82.8%

Net margin

-10.7%

Operating margin

-10.8%

Return on assets

-5.9%

Return on equity

-10.4%

Return on invested capital

-6.1%

Return on capital employed

-5.8%

Return on sales

-8.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Alkermes stock price performed over time

Intraday

-2.16%

1 week

-1.07%

1 month

-14.95%

1 year

-2.41%

YTD

-2.51%

QTD

-2.51%

How have Alkermes's revenue and profit performed over time

Revenue

$1.04B

Gross profit

$860.44M

Operating income

-$112.43M

Net income

-$110.86M

Gross margin

82.8%

Net margin

-10.7%

The net margin has plunged by 70% from the previous quarter but it has grown by 36% YoY

Alkermes's net income has plunged by 51% from the previous quarter but it has increased by 44% YoY

The company's operating margin fell by 38% QoQ but it rose by 28% YoY

Alkermes's operating income has increased by 36% YoY but it has decreased by 23% from the previous quarter

What is Alkermes's growth rate over time

What is Alkermes stock price valuation

P/E

N/A

P/B

2.9

P/S

2.97

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.11

The EPS has dropped by 52% since the previous quarter but it is up by 44% year-on-year

The P/B is 41% lower than the 5-year quarterly average of 4.9 but 12% higher than the last 4 quarters average of 2.6

ALKS's P/S is 54% below its 5-year quarterly average of 6.5 but 19% above its last 4 quarters average of 2.5

The revenue has contracted by 11% from the previous quarter and by 11% YoY

How efficient is Alkermes business performance

The ROS has dropped by 107% since the previous quarter but it is up by 46% year-on-year

The ROIC has plunged by 79% from the previous quarter but it has soared by 59% YoY

The return on equity has dropped by 51% since the previous quarter but it has increased by 43% year-on-year

The ROA fell by 48% QoQ but it rose by 47% YoY

What is ALKS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALKS.

How did Alkermes financials performed over time

Alkermes's total assets is 121% higher than its total liabilities

The company's total liabilities rose by 23% YoY and by 11% QoQ

Alkermes's total assets has increased by 8% YoY and by 3.9% QoQ

The debt is 62% less than the equity

The debt has grown by 41% YoY and by 6% from the previous quarter

The debt to equity is up by 41% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.